Antibody-Drug Conjugate Gets FDA Thumbs Up for Untreated DLBCL

(MedPage Today) -- The FDA approved the antibody-drug conjugate (ADC) polatuzumab vedotin (Polivy) plus standard therapy for certain types of untreated diffuse large B-cell lymphoma (DLBCL), according to a statement from Genentech. The approval...
Source: MedPage Today Public Health - Category: American Health Source Type: news